Brief: Idera Pharmaceuticals Says Will Not Continue Illuminate-301 Trial
18/05/2021 21:32
May 18 (Reuters) - Idera Pharmaceuticals Inc IDRA.O :
* IDERA PHARMACEUTICALS INC - WILL NOT CONTINUE
ILLUMINATE-301
TRIAL
* IDERA PHARMA-DATA DOES NOT SUPPORT LIKELIHOOD THAT
TILSOTOLIMOD
& IPILIMUMAB WOULD ACHIEVE STATISTICALLY SIGNIFICANT OS BENEFIT
OVER IPILIMUMAB ALONE
* IDERA PHARMACEUTICALS - CONTINUING TO ENROLL AND TREAT
PATIENTS
IN ILLUMINATE-206 TRIAL
Source text for Eikon: ID:nGNX7PCNjZ
Further company coverage: IDRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aceragen
See all newsBrief: Aceragen CEO John Taylor's Employment With Co Terminated
Brief: Aceragen Inc To Delist From The Nasdaq Stock Market
Aceragen Inc expected to post a loss of $1.20 a share - Earnings Preview
Brief: Aceragen Board Determined It Is In Best Interests Of Co,To Effect Transfer,Assignment Of All Of Co's Assets To Assignee
Aceragen Inc reports results for the quarter ended in March - Earnings Summary